These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 36514390)
1. Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension. Colglazier E; Stevens L; Parker C; Nawaytou HM; Amin EK; Becerra J; Steurer M; Fineman JR Pulm Circ; 2022 Oct; 12(4):e12159. PubMed ID: 36514390 [TBL] [Abstract][Full Text] [Related]
2. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension. Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912 [TBL] [Abstract][Full Text] [Related]
3. Prostacyclin for pulmonary arterial hypertension. Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry. Lachant D; Minkin R; Swisher J; Mogri M; Zolty R; Hwang S; Seaman S; Broderick M; Sahay S Pulm Pharmacol Ther; 2023 Oct; 82():102232. PubMed ID: 37451609 [TBL] [Abstract][Full Text] [Related]
5. Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series. Blissett S; Blusztein D; Mahadevan VS Eur Heart J Case Rep; 2020 Dec; 4(6):1-7. PubMed ID: 33442633 [TBL] [Abstract][Full Text] [Related]
6. Transitioning Stable Patients with Pulmonary Arterial Hypertension from Parenteral Prostanoids to Oral Selexipag. Hinkamp C; Bartolome S; Mims E; Chin K; Shah T Biomed Hub; 2022; 7(3):115-124. PubMed ID: 36465803 [TBL] [Abstract][Full Text] [Related]
7. Direct prostacyclin transition in pediatric patients with pulmonary hypertension. Merrill K; Davis A; Jackson E; Riker M; Kirk C; Yung D Pulm Circ; 2024 Apr; 14(2):e12373. PubMed ID: 38706991 [TBL] [Abstract][Full Text] [Related]
9. Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension. Radosevich JJ; DeChristopher A; Irandost M; Fann J; Feldman J Am J Health Syst Pharm; 2020 Jul; 77(15):1208-1212. PubMed ID: 32620953 [TBL] [Abstract][Full Text] [Related]
10. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi Kuwano K; Kosugi K; Fuchikami C; Funaki S Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848 [TBL] [Abstract][Full Text] [Related]
11. Transitioning Between Prostanoid Therapies in Pulmonary Arterial Hypertension. Pan IZ; Carey JR; Jacobs JA; Dechand J; Sessions JJ; Sorensen T; Penn BA; Mayeux JD; Hatton ND; Ryan JJ Front Med (Lausanne); 2020; 7():81. PubMed ID: 32296704 [No Abstract] [Full Text] [Related]
12. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy. Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M; J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477 [TBL] [Abstract][Full Text] [Related]
14. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag. Verlinden NJ; Walter C; Raina A; Benza RL J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036 [TBL] [Abstract][Full Text] [Related]
15. Use of selexipag in a teenage patient with pulmonary arterial hypertension. Bravo-Valenzuela NJM; Navarro F; Silva SP Ann Pediatr Cardiol; 2021; 14(1):75-78. PubMed ID: 33679065 [TBL] [Abstract][Full Text] [Related]
16. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy. Adachi S; Nishiyama I; Yasuda K; Yoshida M; Nakano Y; Kondo T; Murohara T J Cardiol Cases; 2022 Jul; 26(1):42-45. PubMed ID: 35923524 [TBL] [Abstract][Full Text] [Related]
17. Different efficacy of inhaled and oral medications in pulmonary hypertension. AbuHalimeh BJ; Parambil JG; Tonelli AR Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831 [TBL] [Abstract][Full Text] [Related]
18. Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients. Aldweib N; Verlinden NJ; Kassis-George H; Raina A Pulm Circ; 2021; 11(4):20458940211036623. PubMed ID: 34646497 [TBL] [Abstract][Full Text] [Related]
19. Selexipag for the treatment of pulmonary arterial hypertension. Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883 [TBL] [Abstract][Full Text] [Related]